Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

Kidney International

Volumn 57, Issue 2, 2000, Pages 601-606

  Andersen, Steen ^a   Tarnow, Lise ^a   Rossing, Peter ^a   Hansen, Birgitte V ^a   Parving, Hans Henrik ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

Glomerular filtration rate; Hypertension; IDDM; Losartan; Proteinuria; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR; ENALAPRIL; HEMOGLOBIN A1C; LOSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0033917552     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00880.x     Document Type: Article

References (33)

1. 1. ANDERSEN AR, CHRISTIANSEN JS, ANDERSEN JK, KREINER S, DECKERI T: Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia 25:496-501, 1983
2. 2. HOMMEL E., PARVING H-H, MATHIESEN ER, EDSBERG B, NIELSEN MD, GIESE J: Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 293:466-470, 1986
3. 3. LEWIS E, HUNSICKER L, BAIN R, RHODE R: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
4. 4. VANHOUTTE PM: Endothelium and control of vascular function. Hypertension 13:658-667, 1989
5. 5. FENOY F, SCICLI G, CARRETERO O, ROMAN RJ: Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 17:1038-1044, 1991
6. 6. GAINER JV, MORROW JD, LOVELAND A, KING DJ, BROWN NJ: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339:1285-1292, 1998
7. 7. HOLLENBERG NK, FISHER NDL, PRICE DA: Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 32:387-392, 1998
8. 8. GANSEVOORT RT, DE ZEEUW D, DE JONG; PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the reninangiotensin system? Kidney Int 45:861-867, 1994
9. 9. PARVING H-H, ANDERSEN AR, SMIDT UM, SVENDSEN PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175-1179, 1983
10. 10. BRÖCHNER-MORTENSEN J, RÖDBRO P: Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36:35-45, 1976
11. 11. BRÖCHNER-MORTENSEN J: A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30:271-274, 1972
12. 12. FELDT-RASMUSSEN B, DINESEN B, DECKERT M: Enzyme immunoassay: An improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 45:539-544, 1985
13. 13. JENSEN T, DECKERT M, DAWNAY A, FELDT-RASMUSSEN B: Micro-ELISA for the quantitation of human urinary and serum retinolbinding protein. Diabetes Res 10:93-95, 1989
14. 14. FOMSGAARD A, FELDT-RASMUSSEN B, DECKERT M, DlNESEN B: Micro-ELISA for the quantitation of human urinary IgG. (technical note) Scand J Clin Lab Invest 47:195-198, 1987
15. 15. MARONI BJ, STEINMAN TI, MITCH WE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27:58-65, 1985
16. 16. KAPPELGAARD AM, NIELSEN MD, GIESE J: Measurement of angiotensin II in human plasma: Technical modifications and practical experience. Clin Chim Acta 67:299-306, 1976
17. 17. PARVING H-H: Renoprotection in diabetes: Genetic and non-genetic risk factors and treatment. Diabetologia 41:745-759, 1998
18. 18. REMUZZI G, BERTANI T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384-394, 1990
19. 19. ROSSING P: Promotion, prediction, and prevention of progression in diabetic nephropathy. Diabet Med 15:900-919, 1998
20. 20. ROSSING P, HOMMEL E, SMIDT UM, PARVING H-H: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 45(Suppl 45):S145-S149, 1994
21. 21. ROSSING P, HOMMEL E, SMIDT UM, PARVING H-H: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37:511-516, 1994
22. 22. BREYER JA, BAIN P, EVANS JK, NAHMAN NS, LEWIS E, COOPER ME, MCGILL JB, BERL T, THE COLLABORATIVE STUDY GROUP: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 50:1651-1658, 1996
23. 23. APPERLOO AJ, DE ZEEUW D, DE JONG PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 45(Suppl 45):S174-S178, 1994
24. 24. KLAHR S, LEVEY AS, BECK GJ, CAGGIULA AW, HUNSICKER L, KUSEK JW, STRIKER G, THE MODIFICATION OF DIET IN RENAL DISEASE STUDY GROUP: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:877-884, 1994
25. 25. KOHZUKI M, YASUJIMA M, KANAZAWA M, YOSHIDA K, FU LP, OBARA K, SAITO ABE K: Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertens 13:97-103, 1995
26. 26. REMUZZI A, FASSI A, SANGAILI F, MALANCHINI B, MOHAMED EI, BERTANT T, REMUZZI G: Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism. Exp Nephrol 6:28-38, 1998
27. 27. YOTSUMOTO T, NAITOH T, SHIKADA K, TANAKA S: Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice. Jpn J Pharmacol 75:59-64, 1997
28. 28. REMUZZI A, RUGGENENTI P, MOSCONI L, PATA V, VIBERTI GC, REMUZZI G: Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 6:36-43, 1993
29. 29. REMUZZI A, PERICO N, AMUCHASTEGUI CS, MALANCHINI B, MAZERSKA M, BATTAGLIA C, BERTANI T, REMUZZI G: Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 4:40-49, 1993
30. 30. KON V, FOGO A, ICHIKAWA I, HEILINGS SE, BILLS T: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 44:545-550, 1993
31. 31. ALLEN TJ, CAO Z, YOUSSEF S, HULTHEN UL, COOPER ME: role of angiotensin II and bradykinin in experimental diabetic nephropathy. Diabetes 46:1612-1618, 1997
32. 32. PITI B, SEGAL R, MARTINEZ FA, MEURFRS G, COWLEY AJ, THOMAS I, DEEDWANIA PC, NEY DE, SNAVELY DB, CHANG PI: Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 347:747-752, 1997
33. 33. DICKSTFIN K, CHANG P, WILLENHEIMER R, HAUNSO S, REMES J, HALL C, KJEKSHUS J: Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 26:438-445, 1995